Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Kishore, Gollamudi S (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07863316
ABSTRACT:
The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patient's blood plasma. The composition also exhibits no food effect.
REFERENCES:
patent: 4389393 (1983-06-01), Schor et al.
patent: 4543370 (1985-09-01), Porter et al.
patent: 4803080 (1989-02-01), Benedikt et al.
patent: 4837223 (1989-06-01), Gobert et al.
patent: 4943639 (1990-07-01), Gobert et al.
patent: 5314697 (1994-05-01), Kwan et al.
patent: 5378474 (1995-01-01), Morella et al.
patent: 5605889 (1997-02-01), Curatolo et al.
patent: 6107492 (2000-08-01), Futagawa et al.
patent: 6274171 (2001-08-01), Sherman et al.
patent: 2004/0062805 (2004-04-01), Vandecruys et al.
patent: 2004/0185097 (2004-09-01), Kannan et al.
patent: 2004/0259933 (2004-12-01), Dolitzky et al.
patent: 2005/0202088 (2005-09-01), Hanshermann et al.
patent: 2006/0008527 (2006-01-01), Lagoviyer et al.
patent: 2006/0269605 (2006-11-01), Lizio et al.
patent: 2007/0105912 (2007-05-01), Holm et al.
patent: 2007/0196481 (2007-08-01), Amidon et al.
patent: 2008/0014264 (2008-01-01), Goffin et al.
patent: 2008/0014271 (2008-01-01), Goffin et al.
patent: 1 118 321 (2001-07-01), None
patent: 1633330 (2007-04-01), None
patent: WO01/51033 (2001-07-01), None
patent: WO 01/151033 (2001-07-01), None
patent: WO 03/039519 (2003-05-01), None
patent: WO03/101428 (2003-12-01), None
patent: WO-03/101428 (2003-12-01), None
patent: WO 03/101428 (2003-12-01), None
patent: WO2004/010998 (2004-02-01), None
patent: WO 2004/105682 (2004-12-01), None
patent: WO2004/108117 (2004-12-01), None
patent: WO2004108117 (2004-12-01), None
patent: WO2006/123357 (2006-11-01), None
patent: WO2007/012439 (2007-02-01), None
patent: WO2007/017249 (2007-02-01), None
patent: WO-2007/017249 (2007-02-01), None
patent: WO2008/062446 (2008-05-01), None
Collins et al., Extended release formulations of anticonvulsant medications, CNS Drugs, 2000, vol. 14, No. 3, p. 203-212.
De Smedt et al., Levetiracetam: Part II, the clinical profile of a novel anticonvulsant drug, CNS Drug Reviews, 2007, vol. 13, No. 1, p. 57-78.
Edwards et al., Levetiracetam levels in human cerebrospinal fluid, AAAN Enterprises, Inc., 2004, vol. 62 (7), supplement S5, p. A118.
Epstein et al., Prolonged neurophysiologic effects of levetiracetam after oral administration in humans, Epilepsia, 2008, 49 (7), p. 1169-1173.
Harden, Safety profile of levetiracetam, Epilepsia, 2001, 42 (suppl.4), p. 36-39.
Patsalos, Clinical Pharmacokinetics of levetiracetam, Clin.Pharm, 2004,43(11), p. 707-724.
Patsalos et al., In Situ metabolism of levetiracetam in blook of patients with epilepsy, Epilepsia, 2006, 47(11), p. 1818-1821.
Radtke, Pharmacokinetics of levetiracetam, Epilepsia, 2001, 42 (suppl. 4), p. 24-27.
Dow Product Brochure, Sep. 2006.
Tong et al., A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain, British Journal of Pharmacology, 2001 133, p. 867-874.
Jinturkar Kaustubh
Kshirsagar Rajesh
Malaviya Nilesh
Rao Ashwin
Hoxie & Associates LLC
Kishore Gollamudi S
Packard Benjamin
UCB Pharma S.A.
LandOfFree
Extended release formulation of Levetiracetam does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Extended release formulation of Levetiracetam, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extended release formulation of Levetiracetam will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2704506